Mylan Acquires Worldwide Rights To Pfizer’s Generic Advair, Seretide

Mylan Inc. Nov. 9 announced that it has entered into an agreement with Pfizer Inc. for the exclusive worldwide rights to develop, manufacture, and commercialize Pfizer’s generic equivalent of GlaxoSmithKline’s Advair Diskus and Seretide Diskus incorporating Pfizer’s proprietary dry power inhaler delivery platform.

Advair Diskus and Seretide Diskus are inhaled fixed-dose combinations of fluticasone propionate and salmeterol delivered via a dry powder inhaler and are used to treat asthma and chronic obstructive pulmonary disorder (COPD), Pittsburgh-based Mylan said.

Additionally, Pfizer will grant Mylan rights to its dry-powder delivery platform to develop and commercialize additional brand and generic pharmaceutical products, including ...